Head-to-head evidence
CKD-701 vs MW02
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
CKD-701
Developed by Chong Kun Dang Pharmaceutical
NCT04857177 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.
MW02
Developed by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05297292 · Phase 2/3 · status unknown
This is a randomized, quadruple-blind, active-controlled Phase 2/3 trial with a clinically meaningful primary endpoint (change in visual acuity), but no results have been posted yet, so the treatment effect versus the active comparator is still unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-701's landscape · MW02's landscape